It has been recently reported that aberrant function of JAK kinases is found often in AML [28], [29], suggesting that JAK1/JAK2 inhibitors may also induce direct negative regulatory effects on AML survival and proliferation. This evidence concerns the gene JAK1 and acute myeloid leukemia.